Copley Scientific has launched a set of tools for inhaler testing qualification called the Flow-Time Verification kit. The kit allows for automatic measurement of flow duration, eliminating the need for stopwatches or the use of invasive measurements. According to the company, "The new Flow-Time Verification kit provides an easy-to-use, non-invasive solution for … [Read more...] about Copley Scientific introduces new verification kit for inhaler testing
News
CHMP issues positive opinion on Adasuve inhaled loxapine
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion regarding Alexza Pharmaceutical's marketing application for Adasuve Staccato loxapine for the treatment of agitation in patients with schizophrenia or bipolar disorder. Alexza filed the MAA in October 2011. According to Alexza, CHMP … [Read more...] about CHMP issues positive opinion on Adasuve inhaled loxapine
“Asthma Inhalers Relief Act of 2012” fails in US House of Representatives
An effort to return remaining units of Primatene Mist epinephrine inhalers to the market failed in the US House of Representatives on December 12, 2012 by a vote of 229-182. Primatene Mist, a CFC-propelled MDI manufactured by Amphastar Pharmaceuticals, was the only over the counter asthma inhaler available in the US until it was removed from the market in accordance … [Read more...] about “Asthma Inhalers Relief Act of 2012” fails in US House of Representatives
Registration for RDD Europe now open
RDD Online and Aptar Pharma have announced that registration for RDD Europe 2013 is now open. The meeting will take place at the Intercontinental Hotel in Berlin, Germany, May 21-24, 2013, with more than 450 OINDP specialists from around the world expected to attend. Dr. D.S.Postma, M.D, Ph.D., Professor at the Department of Pulmonary Medicine and Tuberculosis, … [Read more...] about Registration for RDD Europe now open
Theravance initiates Phase 2b study of investigational LAMA
Theravance has begun a dose ranging Phase 2b study of its TD-4208 inhalation solution in approximately 60 patients with moderate to severe COPD. According to the company, "The goal of Theravance's LAMA program for respiratory disease is to develop a once-daily inhaled medicine in a nebulizer that offers improved efficacy and tolerability relative to current therapies … [Read more...] about Theravance initiates Phase 2b study of investigational LAMA
Aptar increases production capacity for preservative free nasal pumps
Aptar Pharma has "significantly increased" the production capacity at its facility in Eigeltingen, Germany for nasal delivery pumps for preservative free formulations, the company says, in order to meet continuously rising demand for preservative free systems. According to Aptar, the company has already sold more than 130 million units of the Advanced Preservative … [Read more...] about Aptar increases production capacity for preservative free nasal pumps
Aradigm raises $6 million
Aradigm Corporation has agreed to sell 50 million shares of common stock at $0.12 per share to two existing shareholders, generating net proceeds of approximately $5.6 million after fees and expenses. According to Aradigm President and CEO Igor Gonda, the company will use the funds for product development and finding partners for commercialization. The company's … [Read more...] about Aradigm raises $6 million
Clement Clarke launches Flo-Tone inhaler trainer
Device company Clement Clarke International has launched the Flo-Tone MDI trainer, a device that connects to the mouthpiece of a metered dose inhaler to assist patients and healthcare providers in learning proper inhalation technique. The trainer produces an audible tone that indicates when actuation should begin as well as the proper flow rate to ensure optimal … [Read more...] about Clement Clarke launches Flo-Tone inhaler trainer
Tudorza Pressair now available in US
Almirall's Tudorza Pressair aclidinium bromide dry powder inhaler for the maintenance treatment of COPD is now available in the United States, where it is being marketed by Forest Laboratories. The twice-daily anticholinergic was approved in July 2012, as were the European versions of the product, the Eklira and Bretaris Genuair DPIs. Forest and Almirall will … [Read more...] about Tudorza Pressair now available in US
Aptar’s Landmark dose indicator chosen for Skyepharma’s Flutiform MDI
Aptar Pharma has announced the selection of a customized Landmark dose indicator for Skyepharma's Flutiform fluticasone propionate/formoterol fumarate MDI. Flutiform is available for the treatment of asthma in Germany, the UK, and several other countries. The dose indicator on the Flutiform MDI is based on Aptar's Landmark platform, which was the winner of a 2007 … [Read more...] about Aptar’s Landmark dose indicator chosen for Skyepharma’s Flutiform MDI